Rx Communications...

making accurate, valuable information accessible

A Boutique Medical Communications Agency

Why choose Rx Communications?

  • The longest established and largest medical communications agency specialising in health economics and outcomes communications, publications and training
  • One of the most ethical and compliant medical communications agencies in healthcare today
  • A leader in innovative communications and publications, strategic planning and management
Why choose Rx

Customer Testimonials

Sadly, the confidential nature of our work means that our client testimonials are anonymous, but we still think it’s important for you know what they think of us anyway!

I would like to warmly thank you for your great effort and dedication that was put in the development of this Congress report! It was sent out for review to our colleagues.

Strategic Communications Manager

Thanks again for all of your excellent work and help with this manuscript!

Senior Research Advisor

Take it for granted, that I will be back once your help is needed.

Health Economist

Thanks to the Rx team for the beautifully printed poster/minis and for their help with the shipping. All went smoothly – so I really appreciate your help with the logistics.

Research Scientist, Health Technology Assessment

Thanks for all your hard work and the excellently executed workshop. I’m in the middle of my emails but wanted to share this with you…

Scientific Communications Manager

Thank you so much for having your internal reviewers edit these posters. I must say that I was very impressed with their findings, edits, and scientific acumen!

Author & KOL

Latest news from the Health Economics & Outcomes World

  • Could AI in Health Care do More Harm than Good?

    Harvard Law School Professor Jonathan Zittrain recently explored an alternative scenario to artificial intelligence in health care, according to a STAT report, one in which the technology turns into […]

  • ICER: Novartis, J&J Treatments Not...

    Janssen’s Spravato, a depression treatment, and Novartis’ secondary progressive multiple sclerosis (SPMS) drug Mayzent are not cost-effective, the Institute for Clinical and Economic […]

  • PhRMA Offers Recommendations for ICER’s Value...

    The Pharmaceutical Research and Manufacturers of America (PhRMA) recommended five changes the Institute for Clinical and Economic Review (ICER) should make as the drug-pricing watchdog looks to […]

Health Outcomes Communicator (HOC)

Read more

HOC Sign-Up

Get our Health Outcomes Communicator direct to your inbox – sign-up now!

Please note: we will not pass your details on to any third-parties.  View our Privacy Policy here.